Welcome to our dedicated page for Protagonist Therapeutics SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Protagonist Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Protagonist Therapeutics's regulatory disclosures and financial reporting.
Protagonist Therapeutics (PTGX) Form 4: President & CEO Dr. Dinesh V. Patel settled 25,000 performance stock units on 07/21/25 at a cost basis of $0 after the company met pre-set corporate objectives.
To cover related tax obligations, 12,859 shares were immediately sold at a weighted-average price of $54.86. Additional discretionary sales followed: 22,065 shares on 07/22/25 at $55.05 and 17,520 shares on 07/23/25 at $54.79. In total, 52,444 shares were sold for gross proceeds of roughly $2.9 million, trimming Patel’s direct ownership from 583,462 to 531,018 shares—a reduction of about 9%.
No derivative transactions were reported. While the PSU vesting signals successful execution of 2021-vintage performance goals, the scale of secondary sales may draw investor attention to potential insider-sentiment shifts. Patel remains both a director and the largest named executive insider holder.
Protagonist Therapeutics (NASDAQ:PTGX) filed an 8-K reporting the final voting results of its 2025 Annual Meeting held on June 20, 2025.
- Directors elected: Harold E. Selick, Ph.D. (44.8 M for / 9.2 M withheld) and Bryan Giraudo (42.5 M for / 11.5 M withheld) to serve until 2028.
- Say-on-Pay: Executive compensation approved with 50.8 M votes for (92.6% of votes cast).
- Auditor ratification: Ernst & Young LLP confirmed with 55.5 M votes for (99.1%).
No other matters were brought before shareholders, and the meeting produced routine outcomes with no material corporate changes.